| 2 | 1/1 | 返回列表 |
| 查看: 667 | 回復: 1 | |||
| 本帖產生 1 個 翻譯EPI ,點擊這里進行查看 | |||
lijunqing525金蟲 (正式寫手)
|
[求助]
英譯漢 麻煩幫翻譯下
|
||
|
Due to the complex interplay between platelets and monocytes, both alone and together, during immune pathogenesis of HIV infection, it is essential to devise a better methodology to detect PMCs. With this goal in mind, a method to quantitate PMCs in whole blood was standardized and was subsequently employed to assess the percentages of circulating PMCs in blood collected from persons infected with HIV. Although several previous reports have enumerated PMCs using flow cytometry in regard to various disease conditions, the method-ologies used thus far have failed to consider spontaneous platelet activation and the resulting consequence on de novo PMC forma-tion (Gkaliagkousi et al., 2009; Joseph et al., 2001; Ogura et al., 2001; Passacquale et al., 2011; Sevush et al., 1998). Thus, in the efforts to formulate an optimized method for detection of PMCs, fixing the blood samples immediately following collection was given prime importance, as it helped to conserve PMCs and avoid experimen-tal artifacts. Demonstrated herein, is a fix–wash–lyse–wash–stain method to fluorescently label blood samples, which when used along with a progressive gating strategy and FMO (fluorescence minus one) controls, allows for efficient enumeration of PMCs. The additional wash step performed after sample fixation was neces-sary to avoid the toxicity caused by excessive exposure to PFA. One significant concern in adopting this method was that the fixing of samples prior to staining might alter the antibody binding capacity to some extent; however this was deemed a reasonable trade-off given the advantages of this method as outlined above. Nonetheless, in vitro whole blood treatments with LPS and colla-gen were performed, to serve as monocyte and platelet activating reagents, respectively, in order to ensure that it is possible to cap-ture the changes in PMC percentages induced by these treatments using the method of detection described here. Results indicated that platelet–monocyte interaction increased significantly upon platelet activation as compared to monocyte activation. These results corroborate an earlier report by Rinder et al. who showed that platelet–leukocyte complexes increased upon platelet acti-vation and that this interaction was dependent on monocyte activation only to a very limited extent (Rinder et al., 1991). Upon validation of the procedure, persons with or without HIV infection (without any incidence of cardiovascular disease at least one year prior to enrollment in the study) were enrolled to assess whether HIV infection had any effect on platelet–monocyte inter-actions. All of the individuals enrolled in the study were on ART and had low viral load with CD4+ T cell count above 500 cells/mm 3(data not shown). The results show that despite the viral suppres-sion induced by successful ART, the number of circulating PMCs was significantly higher in the inflammatory monocyte subset (i.e. CD16+ monocytes) of these individuals as compared to healthy indi-viduals without HIV infection, and correlated positively with the extent of platelet activation. The PMC percentages in the classi-cal CD16− monocyte subset were also higher in samples obtained from persons infected with HIV, although the effects were not sta-tistically different from controls. Consistently, our data (not shown) and previous reports (Pulliam et al., 1997; Thieblemont et al., 1995) demonstrate a significant increase in CD16+ monocyte percentages in samples obtained from persons infected with HIV. This study defines a flow cytometric method to quantify PMCs in clinical specimens. The findings suggest that persons infected with HIV have increased levels of platelet–monocyte complexes, particularly within the inflammatory monocyte population despite successful ART. Furthermore, this data suggests that either platelets have an increased preference to associate with CD16+ mono-cytes, or that alternatively, the platelet–monocyte cross-talk causes maturation of classical monocytes to the CD16+ phenotype; thus warranting further investigation into whether this interaction enhances the monocyte capacity to cross the blood brain barrier, as well as the role of these monocytes in HIV associated neuro-cognitive impairment. Acknowledgements |

木蟲 (正式寫手)
|
在人類免疫缺陷病毒(HIV)感染的免疫發(fā)病機制中,血小板和單核細胞相互作用,無論是單獨作用還是共同作用,都非常復雜,因此很有必要建立一個能更好地檢測外周血單核細胞(PMC)的方案。懷著這個目標,我們將一個定量檢測全血中PMCs的方法進行標準化,隨后應用它來評定HIV感染者血液標本中循環(huán)PMCs百分比。 盡管以前有幾個關于應用流式細胞儀計數(shù)不同疾病狀態(tài)PMCs的研究報道(Gkaliagkousi et al., 2009; Joseph et al., 2001; Ogura et al., 2001; Passacquale et al., 2011; Sevush et al., 1998),然而他們應用的方法不能解決自發(fā)性血小板激活導致的初始PMC形成這個問題。要構想出最佳的檢測PMCs的方法,血液標本采集后迅速固定極其重要,因為這樣有助于保護PMCs,而且可避免實驗操作導致的人為破壞。 這里介紹的是一種“固定-沖洗-細胞溶解-沖洗-染色”方法檢測熒光標記血液標本。當與漸進門控技術和熒光減一控制技術一起應用時,它可以高效地計數(shù)PMCs。樣本固定后沖洗這一步驟對于避免暴露多聚甲醛(PFA)過多導致的毒性是很有必要的。采用這種方法時一個非常重要的顧慮就是染色之前固定樣本在某種程度上可能會改變抗體的結合能力,然而相對于這種方法的優(yōu)勢來說,這可以認為是一個合理的折衷。雖然如此,體外應用脂多糖(LPS)和膠原蛋白(作為單核細胞和血小板的激活劑)分別處理全血標本,應用這里描述的方法確保能捕捉到這些激活劑誘導的PMC百分比的變化。 結果顯示,與激活單核細胞相比,激活血小板可引起血小板-單核細胞相互作用明顯增加。Rinder等曾研究發(fā)現(xiàn)激活血小板明顯增加血小板-白細胞復合體,這種相互作用很少依賴單核細胞激活(Rinder et al., 1991)。本研究結果與這是一致的。 為了評估這種方法的有效性,本研究納入HIV感染和非HIV感染個體(所有個體納入研究前,至少1年內沒有任何心血管疾病史)評價HIV感染是否對血小板-單核細胞相互作用有影響。本研究納入的所有個體均接受抗逆轉錄病毒治療(ART),處于低病毒載量且CD4+ T細胞含量在500個細胞/mm3時期(數(shù)據未顯示)。 結果顯示,盡管有效的ART會導致病毒抑制,與無HIV感染的健康個體相比,這些個體循環(huán)PMCs中炎性單核細胞亞群(如CD16+單核細胞)數(shù)量明顯增加,并且與血小板激活程度呈正相關。HIV感染者樣本中經典單核細胞(CD16-)亞群百分比有所增高,然而與對照組相比無統(tǒng)計學差異。一致地,我們的結果(未顯示)和以前研究(Pulliam et al., 1997; Thieblemont et al., 1995)結果表明HIV感染者樣本中CD16+單核細胞百分比明顯增加。 這個研究精確地描述了一個量化計數(shù)臨床樣本中PMCs的流式方法。 即使是在有效的ART情況下,這些結果顯示HIV感染者血小板-單核細胞復合體水平明顯增加,尤其是炎性單核細胞亞群。此外,這些結果還顯示血小板優(yōu)先與CD16+單核細胞增加相關,或者CD16+單核細胞優(yōu)先與血小板增加相關;而且血小板-單核細胞交互作用促使經典單核細胞轉變?yōu)槌墒靻魏思毎–D16+)。進而,這可確保我們進一步研究這種相互作用是否會增加單核細胞穿透血腦屏障的能力,以及這些單核細胞在HIV感染相關神經認知損害中作用。致謝! |
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 295材料求調劑,一志愿武漢理工085601專碩 +4 | Charlieyq 2026-03-19 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 290求調劑 +4 | ^O^乜 2026-03-19 | 4/200 |
|
|
[考研] 一志愿蘇州大學材料求調劑,總分315(英一) +3 | sbdksD 2026-03-19 | 3/150 |
|
|
[考研] 0703化學調劑 +10 | 妮妮ninicgb 2026-03-15 | 14/700 |
|
|
[考研] 307求調劑 +9 | 冷笙123 2026-03-17 | 9/450 |
|
|
[考研] 288求調劑,一志愿華南理工大學071005 +5 | ioodiiij 2026-03-17 | 5/250 |
|
|
[考研] 085600材料與化工調劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|
|
[考研] 求調劑,一志愿:南京航空航天大學大學 ,080500材料科學與工程學碩,總分289分 +3 | @taotao 2026-03-19 | 3/150 |
|
|
[考研] 一志愿天大材料與化工(085600)總分338 +5 | 蔡大美女 2026-03-13 | 5/250 |
|
|
[考研] 0817調劑 +3 | 沒有答案_ 2026-03-14 | 3/150 |
|
|
[考研] 08工科 320總分 求調劑 +5 | 梨花珞晚風 2026-03-17 | 5/250 |
|
|
[考研] 材料,紡織,生物(0856、0710),化學招生啦 +3 | Eember. 2026-03-17 | 9/450 |
|
|
[考研] 301求調劑 +4 | A_JiXing 2026-03-16 | 4/200 |
|
|
[考研] 有沒有道鐵/土木的想調劑南林,給自己招師弟中~ +3 | TqlXswl 2026-03-16 | 7/350 |
|
|
[考研] 材料與化工專碩調劑 +5 | heming3743 2026-03-16 | 5/250 |
|
|
[考研] 302求調劑 +4 | 小賈同學123 2026-03-15 | 8/400 |
|
|
[考研] 東南大學364求調劑 +5 | JasonYuiui 2026-03-15 | 5/250 |
|
|
[考研] 333求調劑 +3 | 文思客 2026-03-16 | 7/350 |
|
|
[考研] 304求調劑 +5 | 素年祭語 2026-03-15 | 5/250 |
|
|
[考研] 327求調劑 +6 | 拾光任染 2026-03-15 | 11/550 |
|